| Timothy Sowder, | |
|
Kumc 3901 Rainbow Blvd Ms 1034, Kansas City, KS 66160-0001 | |
| (913) 588-3302 | |
| (913) 588-3365 |
| Full Name | Timothy Sowder |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 10 Years |
| Location | Kumc 3901 Rainbow Blvd Ms 1034, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013328053 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 9408323 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
Affymetrix, Inc. today announced that the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the University of California at San Francisco (UCSF) have entered into an agreement with Affymetrix to support genome-wide analyses of DNA samples from 100,000 Kaiser Permanente members.
Finding ways to help patients with COPD improve their functional status is an area of interest for pulmonary healthcare providers. Currently, pulmonary rehabilitation (PR) is used where available to improve exercise capacity and quality of life, but the treatment requires access to trained staff and specialized facilities.
A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
› Verified 4 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Affymetrix, Inc. today announced that the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the University of California at San Francisco (UCSF) have entered into an agreement with Affymetrix to support genome-wide analyses of DNA samples from 100,000 Kaiser Permanente members.
Finding ways to help patients with COPD improve their functional status is an area of interest for pulmonary healthcare providers. Currently, pulmonary rehabilitation (PR) is used where available to improve exercise capacity and quality of life, but the treatment requires access to trained staff and specialized facilities.
A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy Sowder, Kumc 3901 Rainbow Blvd Ms 1034, Kansas City, KS 66160-0001 Ph: (913) 588-3302 | Timothy Sowder, Kumc 3901 Rainbow Blvd Ms 1034, Kansas City, KS 66160-0001 Ph: (913) 588-3302 |
News Archive
Affymetrix, Inc. today announced that the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the University of California at San Francisco (UCSF) have entered into an agreement with Affymetrix to support genome-wide analyses of DNA samples from 100,000 Kaiser Permanente members.
Finding ways to help patients with COPD improve their functional status is an area of interest for pulmonary healthcare providers. Currently, pulmonary rehabilitation (PR) is used where available to improve exercise capacity and quality of life, but the treatment requires access to trained staff and specialized facilities.
A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
› Verified 4 days ago
Lyna Rehan, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd # Ms 1034, Kansas City, KS 66160 Phone: 913-588-3304 Fax: 913-588-3365 | |
Dr. Joel Kent Grigsby, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-3315 | |
O. Layton Alldredge Jr., MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Kansas University Medical Ctr, 3901 Rainbow Blvd Ms 1034, Kansas City, KS 66160 Phone: 913-588-3304 | |
Robert P Devine, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-3315 | |
Jennifer B Kenny, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Mail Stop 1034, Kansas City, KS 66160 Phone: 913-588-3315 Fax: 913-588-3365 | |
Dr. Sarafina Kristine Kankam, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-5000 |